Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy

European Journal of Internal Medicine

Volumn 16, Issue 5, 2005, Pages 352-355

  Sahin, Mustafa ^a,b   Erdogan, Murat Faik ^a   Erdogan, Gurbuz ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Antithyroid therapy; CTLA 4 (cytotoxic T lymphocyte associated molecule 4); Graves' disease; Remission

Indexed keywords

ANTITHYROID AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROPRANOLOL; THYROID HORMONE; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENOTYPE; GOITER; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; STATISTICAL SIGNIFICANCE; THYROID HORMONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 28744459212     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2005.06.007     Document Type: Article

References (20)

1. M.E. Fisfalen, K. Soltani, E. Kaplan, E.M. Palmer, G.A. van Seventer, and F.H. Straus Evaluating the role of Th0 and Th1 clones in autoimmune thyroid disease by use of Hu-SCID chimeras Clin Immunol Immunopathol 85 1997 253 264
2. B.A. Kallmann, M. Huther, M. Tubes, J. Feldkamp, J. Bertrams, and F.A. Gries Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease Diabetes 46 1997 237 243
3. T.F. Davies Graves' disease: Pathogenesis L.E. Braverman R.D. Utiger Werner and Ingbar's the thyroid: a fundamental and clinical text 2000 Lippincott, Williams & Wilkins Philadelphia 518 530
4. M.A. Oosterwegel, R.J. Greenwald, D.A. Mandelbrot, R.B. Lorsbach, and A.H. Sharpe CTLA-4 and T cell activation Curr Opin Immunol 11 1999 294 300
5. T. Yanagawa, M. Taniyama, S. Enomoto, K. Gomi, H. Maruyama, and Y. Ban CTLA 4 gene polymorphism confers susceptibility to Graves' disease in Japanese Thyroid 7 1997 843 846
6. T. Yanagawa, Y. Hidaka, V. Guimaraes, M. Soliman, and L.J. DeGroot CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population J Clin Endocrinol Metab 80 1995 41 45
7. H. Donner, H. Rau, P.G. Walfish, J. Braun, T. Siegmund, and R. Finke CTLA 4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus J Clin Endocrinol Metab 82 1997 143 146
8. E.A. Tivol, A.N. Schweitzer, and A.H. Sharpe Costimulation and autoimmunity Curr Opin Immunol 8 1996 822 830
9. T.L. Walunas, D.J. Lenschow, C.Y. Bakker, P.S. Linsley, G.J. Freeman, and J.M. Greene CTLA-4 can function as a negative regulator of T-cell activation Immunity 1 1994 405 413
10. C.A. Chambers, M.F. Krummel, B. Boitel, A. Hurwitz, T.J. Sullivan, and S. Fournier The role of CTLA-4 in the regulation of T-cell responses Immunol Rev 153 1996 27 46
11. M. Mäurer, S. Loserth, A. Kolb-Maurer, A. Ponath, S. Wiese, and N. Kruse A polymorphism in human cytotoxic T lymphocyte antigen 4 (CTLA-4) gene (exon 1+49) alters T cell activation Immunogenetics 54 2002 1 8
12. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction: revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
13. J.M. Heward, A. Allahabadia, M. Armitage, A. Hattersley, P.M. Dodson, and K. Macleod The development of Graves' disease and the CTLA-4 gene on chromosome 2q33 J Clin Endocrinol Metab 84 1999 2398 2401
14. D.A. Chistyakov, K.V. Savost'anov, R.I. Turakulov, N.A. Petunina, L.V. Trukhina, and A.V. Kudinova Complex association analysis of Graves' disease using a set of polymorphic markers Mol Genet Metab 70 2000 214 218
15. T. Kouki, C.A. Gardine, T. Yanagawa, and L.J. Degroot Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease J Endocrinol Invest 25 2002 208 213
16. Y. Tomer, D.A. Greenberg, G. Barbesino, E. Concepcion, and T.F. Davies CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production J Clin Endocrinol Metab 86 2001 1687 1693
17. T. Kouki, Y. Sawai, C.A. Gardine, M.E. Fisfalen, M.L. Alegre, and L.J. DeGroot CTLA4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease J Immunol 165 2000 6606 6611
18. J.R. Abram, M.G. Lebwohl, C.A. Guzzo, B.V. Jegasothy, M.T. Goldfarb, and B.S. Goffe CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 1999 1243 1252
19. Y. Kinjo, N. Takasu, I. Komiya, T. Tomoyose, M. Takara, and T. Kouki Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene J Clin Endocrinol Metab 87 2002 2593 2596
20. P.W. Wang, R.T. Liu, S.H. Juo, S.T. Wang, Y.H. Hu, and C.J. Hsieh Cytotoxic, lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal J Clin Endocrinol Metab 89 1 2004 (Jan.) 169 173